R&D READING
From screening to medicine: how evidence accumulates
Candidate discovery, validation, clinical research, regulatory review and post-marketing monitoring answer different questions along one development path.
Discovery is not a promise
A target hypothesis, a molecular hit or an in-vitro result is early evidence, not a conclusion about a medicine. Development teams repeatedly test whether a biological signal can be reproduced, whether a candidate can be delivered as a suitable product and whether its safety margin supports further work.
Clinical studies answer defined questions
A clinical study is designed around a specified population, endpoint and method. Its findings need to be read with the design, sample, comparator and authorised indication in view. A single paper or news headline cannot establish benefit for every population or use.
Approval is followed by more records
After marketing authorisation, labels, safety information and regulatory communications can change. A medicine record should preserve a timeline and source links rather than treat one approval event as the final answer.
PRIMARY REFERENCE